BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1889339)

  • 1. [Combination treatment of acute non-lymphocytic leukemia with HOAP and AA--preliminary report of 14 cases].
    Zhang GZ
    Zhonghua Zhong Liu Za Zhi; 1991 Jan; 13(1):52-4. PubMed ID: 1889339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HOAP/HOAGP in the treatment of acute non-lymphocytic leukemia: an analysis of 68 cases].
    Shan YD
    Zhonghua Yi Xue Za Zhi; 1985 Oct; 65(10):590-2. PubMed ID: 3938671
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases.
    Zhang ZY; Hou CH; Zhu YF; You XY; Li JL; Fu Z
    Chin Med J (Engl); 1987 Jul; 100(7):565-8. PubMed ID: 3123163
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults].
    Li QH; DU X; Huang ZL; Luo CW; Zhong LY; Lin W
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(17):1195-7. PubMed ID: 16029595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Low-dose ARA-C and HOAAP regimen in the treatment of adult acute nonlymphocytic leukemia: analysis of 59 cases].
    Dong ZR; Yao EG; Xu SR
    Zhonghua Nei Ke Za Zhi; 1988 May; 27(5):300-2, 327. PubMed ID: 3197499
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapeutic effects of chemotherapeutic regimen with pirarubicin for adult high-risk acute leukemia].
    Huang F; Meng FY; Xue B; Liu XL; Zhang Y; Ye CX; Zhang X
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jul; 24(7):768-70. PubMed ID: 15257898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City].
    Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):139-42, 187. PubMed ID: 1395923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
    Hewlett JS; Chen T; Balcerzak SP; Gutterman JU; Costanzi JJ; Amare M
    Arch Intern Med; 1985 Jun; 145(6):1006-12. PubMed ID: 3890786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute promyelocytic leukemia with all-trans retinoic acid. A five-year experience.
    Sun GL; Ouyang RR; Chen SJ; Gu YZ; Huang LA; Lu JX; Wang ZY
    Chin Med J (Engl); 1993 Oct; 106(10):743-8. PubMed ID: 8033606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OAP combination in the treatment of elderly leukaemic patients with preexisting severe internal disease.
    Marra R; Pagano L; Liene DR; Storti S; Girasoli M; Leone G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):187-91. PubMed ID: 2475396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
    Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
    Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Late results of the treatment of acute granulocytic leukemia in adults].
    Perilov AA; Volkova MA; Frenkel' MA
    Ter Arkh; 1989; 61(7):8-11. PubMed ID: 2588148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
    Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT
    Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.